Nebivolol treatment improves hypertension-induced endothelial cell dysfunction by reducing TGF-β1-dependent senescence and normalizing mitochondrial indices.
J HypertensJul 29, 2026 (epub)
Paweł Uruski, Justyna Mikuła-Pietrasik, Andrzej Tykarski et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial studied 71 patients with newly diagnosed hypertension to evaluate the effects of antihypertensive treatments on endothelial cell function. Nebivolol treatment significantly improved endothelial cell activity by reducing TGF-β1-dependent senescence and oxidative stress, demonstrating the most consistent benefits compared to amlodipine and perindopril.
Key findings
- Nebivolol treatment reduced senescence biomarkers such as SA-β-Gal and p16.
- Serum from nebivolol-treated patients showed lower levels of pro-inflammatory cytokines.
- Nebivolol significantly decreased oxidative stress, indicated by lower oxidized DNA product levels.
- HIF-1α expression was reduced in endothelial cells exposed to serum from nebivolol-treated patients.
Why it matters
Understanding the impact of antihypertensive treatments on endothelial function is crucial, as endothelial dysfunction is a key factor in cardiovascular disease progression. This study highlights nebivolol's potential to mitigate hypertension-induced endothelial damage.